References of "Milpied, N"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailModalités de conservation et de destruction des produits cellulaires cryopréservés : recommandations de la SFGM-TC
CALMELS, ; Boulanger, F; BAUDOUX, Etienne ULg et al

in Pathologie et Biologie (2014), 62(3),

Thousands of autologous and at less extent allogeneic hematopoietic stem cells (HSC) bags are cryopreserved in France. The majority of autologous HSC grafts are used within a year after collection ... [more ▼]

Thousands of autologous and at less extent allogeneic hematopoietic stem cells (HSC) bags are cryopreserved in France. The majority of autologous HSC grafts are used within a year after collection. However, many bags are still unused and cryopreserved for many years. In France and on a European scale, the ever-growing number of cryopreserved bags represents a real economic health concern. Indeed, the cost of storage is about 100 € per bag and per year. In addition, quality and therapeutic value of these long-term cryopreserved grafts needs to be evaluated. In the attempt to harmonize clinical practices between different French transplantation centers, the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC) set up its fourth annual series of workshops which brought together practitioners from its member centers across France. These workshops took place in September 2013 in Lille. In this article, we addressed the issue of the destruction of long-term cryopreserved grafts be them autologous or allogeneic and provide recommendations regarding their destruction. [less ▲]

Detailed reference viewed: 9 (4 ULg)
Full Text
Peer Reviewed
See detailOutcomes of adults with active or progressive hematological malignancies at time of allogeneic stem cell transplantation : a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
Chevallier, P.; Labopin, M.; Milpied, N. et al

in Bone Marrow Transplantation (2014), 49

Previous data suggested that allo-SCT might be an effective therapy in the setting of chemo-refractory/relapsed diseases because of the potent long-term immune-mediated tumor control. This retrospective ... [more ▼]

Previous data suggested that allo-SCT might be an effective therapy in the setting of chemo-refractory/relapsed diseases because of the potent long-term immune-mediated tumor control. This retrospective study aimed to analyze the outcome of adult patients who received allo-SCT in a chemo-refractory/relapsed status. The series included 840 patients with active or progressive disease at the time of transplant. Median age was 50 years. With a median follow-up of 40 months, 3-year OS, disease-free survival (DFS), and non-relapse mortality rates were 29±2, 23±2, and 30±2%, respectively. At the last follow-up, 252 patients (30%) were still alive (of whom 201 were in CR (24%). In a Cox multivariate analysis, the use of a reduced-intensity conditioning (RIC) before allo-SCT and use of an HLA-identical sibling donor remained independently associated with a better OS (hazard ratio (HR)¼0.82; 95% confidence interval (CI), 0.69–0.98, P¼0.03; and HR¼0.79; 95% CI, 0.66–0.93, P¼0.006, respectively). Also, a diagnosis of myelodysplastic syndrome/myeloproliferative disorder, Hodgkin lymphoma and non-Hodgkin lymphoma compared with acute leukemia had a favorable impact on OS (HR¼0.55; 95% CI, 0.45–0.68, Po0.0001; HR¼0.49; 95% CI, 0.31–0.75, P¼0.001; and HR¼0.47; 95% CI, 0.35–0.63, Po0.0001, respectively). In conclusion, this study suggests that allo-SCT may be of benefit in some subgroups of patients with active or progressive hematological malignancies at the time of allo-SCT. [less ▲]

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailUnrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia : a survey on behalf of Eurocord and CLWP of EBMT
Robin, M.; Sanz, G. F.; Ionescu, I. et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2011), 25

Detailed reference viewed: 12 (3 ULg)